Home » Topics » BioWorld Science

BioWorld Science
RSS

First patient enrolled in phase III trial of topical ocular reproxalap

April 25, 2018

Results on sodium oxybate presented in pediatric patients with narcolepsy type 1

April 25, 2018

Third Rock Ventures launches Cedilla Therapeutics

April 25, 2018

Completion of phase I study of tozuleristide in pediatric brain tumor surgery

April 25, 2018

Nektar, Takeda to evaluate NKTR-214 in combination with TAK-659

April 25, 2018

Initiation of phase Ib trial of CMP-001 plus atezolizumab in anti-PD-1/PD-L1 resistant NSCLC

April 25, 2018

Procalcitonin predicts malignant cerebral edema after massive cerebral infarction

April 25, 2018

U.S. Navy describes novel anti-CD20 antibodies

April 25, 2018

Afecta Pharmaceuticals patents novel hgh mobility group protein B1 inhibitors

April 25, 2018

Galapagos initiates clinical trial with triple combination therapy in cystic fibrosis

April 25, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...